Cantor Fitzgerald Reaffirms Overweight Rating for Organogenesis (NASDAQ:ORGO)

Cantor Fitzgerald restated their overweight rating on shares of Organogenesis (NASDAQ:ORGOFree Report) in a research note issued to investors on Friday morning, Benzinga reports. Cantor Fitzgerald currently has a $5.00 price objective on the stock.

Several other research analysts have also recently weighed in on the stock. BTIG Research boosted their price objective on shares of Organogenesis from $4.00 to $6.00 and gave the company a buy rating in a report on Wednesday, December 27th. Morgan Stanley increased their price target on Organogenesis from $3.00 to $3.50 and gave the company an equal weight rating in a report on Tuesday, November 14th.

Check Out Our Latest Report on ORGO

Organogenesis Trading Down 1.4 %

Shares of NASDAQ:ORGO opened at $2.88 on Friday. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.80 and a quick ratio of 2.44. Organogenesis has a 1 year low of $1.79 and a 1 year high of $4.70. The company has a market cap of $380.04 million, a P/E ratio of 72.02 and a beta of 1.59. The stock’s fifty day moving average price is $3.69 and its 200-day moving average price is $3.05.

Insider Buying and Selling at Organogenesis

In other news, major shareholder Albert Erani sold 197,921 shares of Organogenesis stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $4.37, for a total transaction of $864,914.77. Following the transaction, the insider now owns 59,025,106 shares in the company, valued at approximately $257,939,713.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 34.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. raised its stake in Organogenesis by 80.1% during the 1st quarter. Ameritas Investment Partners Inc. now owns 5,386 shares of the company’s stock worth $41,000 after acquiring an additional 2,396 shares during the period. Point72 Hong Kong Ltd lifted its stake in shares of Organogenesis by 245.7% during the 2nd quarter. Point72 Hong Kong Ltd now owns 6,015 shares of the company’s stock valued at $29,000 after buying an additional 4,275 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Organogenesis by 94.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,663 shares of the company’s stock valued at $27,000 after buying an additional 3,235 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in Organogenesis by 3,808.2% in the 1st quarter. Lazard Asset Management LLC now owns 9,106 shares of the company’s stock worth $69,000 after buying an additional 8,873 shares during the period. Finally, Principal Financial Group Inc. purchased a new stake in Organogenesis in the 3rd quarter worth $32,000. 39.48% of the stock is owned by hedge funds and other institutional investors.

Organogenesis Company Profile

(Get Free Report)

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly, a antimicrobial barrier that enables conformability and fluid drainage.

Read More

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.